Literature DB >> 20168332

Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine.

L Anastasia1, G Pelissero, B Venerando, G Tettamanti.   

Abstract

The possibility of reprogramming adult somatic cells into pluripotent stem cells (iPSCs) has generated a renewed interest into stem cell research and promises to overcome several key issues, including the ethical concerns of using human embryonic stem cells and the difficulty of obtaining large numbers of adult stem cells (Belmonte et al., Nat Rev Genet, 2009). This approach is also not free from challenges like the mechanism of the reprogramming process, which has yet to be elucidated, and the warranties for safety of generated pluripotent cells, especially in view of their possible therapeutic use. Very recently, several new reprogramming methods have surfaced, which seem to be more appropriate than genetic reprogramming. Particularly, chemically induced pluripotent cells (CiPSs), obtained with recombinant proteins or small synthetic molecules, may represent a valid approach, simpler and possibly safer than the other ones.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20168332     DOI: 10.1038/cdd.2010.14

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  15 in total

Review 1.  Generation of pluripotent stem cells without the use of genetic material.

Authors:  Akon Higuchi; Qing-Dong Ling; S Suresh Kumar; Murugan A Munusamy; Abdullah A Alarfaj; Yung Chang; Shih-Hsuan Kao; Ke-Chen Lin; Han-Chow Wang; Akihiro Umezawa
Journal:  Lab Invest       Date:  2014-11-03       Impact factor: 5.662

Review 2.  Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives.

Authors:  Alexander E Berezin
Journal:  World J Diabetes       Date:  2014-12-15

3.  A chemical approach to myocardial protection and regeneration.

Authors:  Marco Piccoli; Federica Cirillo; Guido Tettamanti; Luigi Anastasia
Journal:  Eur Heart J Suppl       Date:  2016-04-29       Impact factor: 1.803

4.  The prospect of induced pluripotent stem cells for diabetes mellitus treatment.

Authors:  Andreas Soejitno; Pande Kadek Aditya Prayudi
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

5.  Reversine, a 2,6-disubstituted purine, as an anti-cancer agent in differentiated and undifferentiated thyroid cancer cells.

Authors:  Shih-Che Hua; Tien-Chun Chang; Hau-Ren Chen; Chieh-Hsiang Lu; Yi-Wen Liu; Shu-Hsin Chen; Hui-I Yu; Yi-Ping Chang; Ying-Ray Lee
Journal:  Pharm Res       Date:  2012-04-04       Impact factor: 4.200

Review 6.  All roads lead to induced pluripotent stem cells: the technologies of iPSC generation.

Authors:  Kejin Hu
Journal:  Stem Cells Dev       Date:  2014-03-21       Impact factor: 3.272

Review 7.  Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases.

Authors:  Lei Cao; Lan Tan; Teng Jiang; Xi-Chen Zhu; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2014-08-23       Impact factor: 5.590

Review 8.  Derivation of human induced pluripotent stem cells for cardiovascular disease modeling.

Authors:  Kamileh Narsinh; Kazim H Narsinh; Joseph C Wu
Journal:  Circ Res       Date:  2011-04-29       Impact factor: 17.367

9.  Synergistic antitumor activity of reversine combined with aspirin in cervical carcinoma in vitro and in vivo.

Authors:  Hai-Xia Qin; Jun Yang; Hong-Kai Cui; Shao-Ping Li; Wei Zhang; Xiao-Li Ding; Yong-Hua Xia
Journal:  Cytotechnology       Date:  2013-03-10       Impact factor: 2.058

Review 10.  Embryonic stem cells and inducible pluripotent stem cells: two faces of the same coin?

Authors:  Francesco Romeo; Francesco Costanzo; Massimiliano Agostini
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.